Sexually Transmitted Disease Testing Market Analysis

Disease (Human Immunodeficiency Virus, Herpes Simplex Virus, Human Papillomavirus, Chlamydia, Syphilis, Gonorrhea, Cancroid)

The global sexually transmitted disease testing market is segmented and analyzed for demand and supply by disease into human immunodeficiency virus, herpes simplex virus, human papillomavirus, chlamydia, syphilis, gonorrhea, cancroid, and others. Out of these, the chlamydia segment is expected to garner the highest revenue by the end of 2037. This can be attributed to the higher instances of chlamydia in the younger population owing to unprotected sex and in adults owing to involvement with different partners. Furthermore, there has been surging awareness related to chlamydia treatment, that is further predicted to boost the segment’s growth in the market. According to the World Health Organization, in 2020 there was nearly 129 million instances of chlamydia around the world. The Center for Disease Control and Prevention reported a total of 1,808,703 cases of chlamydia in 2019.

Location (Laboratory, Point of Care)

The STD Testing Market is segmented by location into laboratory and point of care. Out of these, the laboratory segment is expected to garner highest revenue, as laboratories are the most commonly used place for assessing Sexually Transmitted Diseases (STDs) worldwide. The blood screening is performed in laboratories with proper care in order to give correct results, and it is predicted to surge the segment’s growth in the market. Moreover, laboratory tests are precise and trustworthy, their use is widespread, and people place more faith in them, that is further anticipated to surge the segment’s growth in the market. Abbott laboratories provide an in vitro reverse transcription-polymerase chain reaction (RT-PCR) test and an in vitro polymerase chain reaction (PCR) assay for the identification of sexually transmitted diseases induced by Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium, including gonorrhea. Correspondingly, Qiagen Inc. offers a diverse selection of screening test kits, along with STI assessments for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections with significant clinical sensitiveness and specificity, that are utilized to identify a variety of sexually transmitted diseases. More product introductions enable laboratories to configure devices or machinery as needed. For instance, with European Commission authorization, Qiagen Inc. released the NeuMoDxHSV 1/2 Quant Test for the measurement and distinction of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) in May 2022. These factors, as a result, are anticipated to create numerous opportunities for the growth of the segment in the coming years.

Our in-depth analysis of the global market includes the following segments: